Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome

Leonard Izzard, Daniel Dlugolenski, Yingju Xia, Meagan McMahon, Deborah Middleton, Ralph A. Tripp, John Stambas

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Influenza A vaccine efficacy in the elderly is generally poor and so identification of novel molecular adjuvants to improve immunogenicity is important to reduce the overall burden of disease. Short non-coding RNAs, known as microRNAs (miRNAs) are known to regulate gene expression and have the potential to influence immune responses. One such miRNA, miR-155, has been shown to modulate T and B cell development and function. We incorporated miR-155 into the influenza A virus (IAV) genome creating a self-adjuvanting ‘live vaccine’ with the ability to modify immunogenicity. Infection of mice with a recombinant influenza virus encoding miR-155 in the NS gene segment altered epitope-specific expansion of influenza-specific CD8+ T cells and induced significantly higher levels of neutralising antibody.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalVirus Research
Publication statusPublished - 2 May 2017
Externally publishedYes


Dive into the research topics of 'Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome'. Together they form a unique fingerprint.

Cite this